Breast Cancer – Medical News Asia

Reporting HER2 IHC in 2026: CAP-Aligned Reporting Across Tumor Types and the Impact of Intratumoral Heterogeneity

REFINING HER2 IHC ASSESSMENT GUIDED BY CAP REPORTING TEMPLATE: ENABLING ACCURATE CLASSIFICATION ACROSS SOLID TUMORS AND ADDRESSING INTRATUMORAL HETEROGENEITY

24 June 2026/in Pantumor, Overexpression, HER2, HER2 Explorer, Breast Cancer, Gastrointestinal Cancer 2nd Homepage/by Reema Subramanian

The use of IHC staining of tissue samples to guide targeted treatment is widely used in clinical practice, and is recommended by expert groups for many tumor types and biomarkers. [11,12] The classical approach to IHC scoring for biomarkers, such as human epidermal growth factor receptor-2 (HER2), classifies specimens as either ‘positive’ or ‘negative’, scoring samples as IHC0, 1+, 2+ or 3+ per pathologists’ visual interpretation. [11,12]

Navigating HER2 Testing: Unveiling the Strengths and Limitations to Optimize Biomarker Assessment

31 July 2025/in HER2 Explorer, Breast Cancer 2nd Homepage/by Stijn van den Borne, MSc

Due to the availability of human epidermal growth factor receptor 2 (HER2)-directed therapies, testing for HER2 alterations, including overexpression, gene amplification or mutations is recommended in treatment guidelines for various tumor types, including breast cancer, gastric cancer, biliary tract cancer, cervical cancer, colorectal cancer, non-small cell lung cancer (NSCLC), and others.1-10

NEPA as an Effective Therapeutic Approach for Managing ADC-Induced Nausea and Vomiting

20 August 2024/Enter your password to view comments./in Breast Cancer, Therapeutic Areas, Oncology, AE Management In Depth/by Jessica LAU

There is no excerpt because this is a protected post.

MHK-FOS-2024019 Case Sharing interview 2 KV

Effective Management of Chemotherapy-Induced Nausea and Vomiting (CINV) in a Patient Receiving T-DXd for Triple-Positive Breast Cancer

11 July 2024/Enter your password to view comments./in Therapeutic Areas, Breast Cancer, Oncology, AE Management In Depth/by Jessica LAU

There is no excerpt because this is a protected post.

More Severe Outcomes in COVID-19 Patients with Cancer

16 May 2022/0 Comments/in Breast Cancer, COVID-19, Haematology, Infectious Disease, Lung Cancer, Oncology, Chemotherapy, Immunotherapy/by Christy Leung

Severe COVID-19 infection does not only bring about patient distress, but also increases public health expenditure in supportive devices such as ventilators. It is necessary to minimise the risk of COVID-19 infection in cancer patients, considering COVID-19 waves are likely to recur regularly and they are the high-risk groups. Personal hygiene measures and COVID-19 vaccination have been demonstrated to be efficacious and should be recommended to cancer patients for lowering the likelihood of hospitalisation, ICU admission and mortality.

Abemaciclib: A review of the evidence through clinical cases

25 March 2021/in Breast Cancer, Oncology, Chemotherapy, Endocrine Therapy, Radiology, Targeted Therapies/by Kirsty LEE

There is no excerpt because this is a protected post.

Breast cancer update January 2021

1 February 2021/in Breast Cancer, Oncology, Chemotherapy, Endocrine Therapy, Radiology, Targeted Therapies, Translational Research/by Kirsty LEE

With the San Antonio Breast Cancer Conference (SABCS) 2020 by AACR just completed, several new and clinical relevant phase 2 and phase 3 have been published in the Journal of the American Medical Association, Clinical Cancer Research, New England Journal of Medicine, Journal of Clinical Oncology, and Lancet Oncology. [‘mediPr] provides you with an overview.

First liquid biopsy for NSCLC to receive FDA approval

7 September 2020/0 Comments/in Breast Cancer, Gastrointestinal Cancer, Genitourinary Cancer, US FDA Onc\Haem Approvals, Gynaecological Cancer, Lung Cancer, Oncology, Targeted Therapies/by Kirsty LEE

The development of new targeted therapies for non-small cell lung cancer (NSCLC) in recent years has changed the standard of care for the later stages of NSCLC in specific population groups.

ESMO releases the first guideline on NGS testing in cancers

7 September 2020/0 Comments/in Breast Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Gynaecological Cancer, Lung Cancer, Oncology, Targeted Therapies, Pathology/by Kirsty LEE

Precision therapies were first approved for cancer in 1998, when trastuzumab was approved for HER2+ breast cancer, opening the door for other targeted therapies such as imatinib for Philadelphia chromosome-positive chronic myelogenous leukaemia.

ASCO-2020-ASCO20-virtual-meeting-NSCLC-SCLC-lung-cancer-breast-cancer-hepatocellular-cancer-HCC-colorectal-cancer-CRC-e1593749874717

ASCO 2020 Lung, Breast, and Liver Cancer Update

30 June 2020/0 Comments/in Breast Cancer, China, Conferences, Gastrointestinal Cancer, Lung Cancer, Oncology, ASCO 2020 Annual Meeting, Chemotherapy, Endocrine Therapy, Immunotherapy, Targeted Therapies/by Kirsty LEE

This year, ASCO 2020 was held as a virtual conference due to the COVID-19 pandemic. This is a summary of key trials presented at ASCO, focusing primarily on breast cancer, liver cancer, and lung cancer.